2025年5月24日 周六
Home > Archive>Volume 26, Issue 2, 2018 >213-216
PDF HTML XML Export Cite reminder
Research progress of the relationship between interleukin-37 and atherosclerosis
Author:
Affiliation:

Emergency Department of General Hospital of Civil Aviation, Beijing 100123, China)

Clc Number:

R543.5

  • Article
    • | |
  • Metrics
    • |
  • Reference [25]
    • | | | |
  • Comments
    Abstract:

    As a chronic inflammatory disease of blood vessel, atherosclerosis(As)is the main cause of coronary heart disease, cerebral infarction and peripheral vascular disease, which seriously threatens the health and life of human beings. As a new type of anti-inflammatory molecules of the interleukin-1 family, interleukin-37 plays an important biological function in a variety of inflammatory diseases, neoplastic disease and autoimmune diseases. The anti-inflammatory effects of interleukin-37 may be related to interleukin-18 binding protein and Smad3. Clinical and animal experiments have confirmed that interleukin-37 is involved in the development of As and may annihilate the progression of As by inhibiting the functions of macrophages, mast cells and dendritic cells.

    Reference
    [1] Nold MF, Nold-Petry CA, Zepp JA, et al.IL-37 is a fundamental inhibitor of innate immunity .Nat Immunol, 2010, 11(11): 1 014-022.
    [2] Boraschi D, Lucchesi D, Hainzl S, et al.IL-37: a new anti-inflammatory cytokine of the IL-1 family .Eur Cytokine Netw, 2011, 22(3): 127-147.
    [3] Kumar S, Mc Donnell PC, Lehr R, et al.Identification and initial characterization of four novel members of the interleukin-1 family .J Biol Chem, 2000, 275(14): 10 308-314.
    [4] Taylor SL, Renshaw BR, Graka KE, et al.Genomic organization of the interleukin-1 locus.Genomics, 2002, 79(5): 726-733.
    [5] Bachereau J, Pascual VO, Garra A.From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines .Nat Immunol, 2012, 13(10): 925-931.
    [6] Kumar S, Hanning CR, Brigham-Burke MR, et al.Interleukin-1f7b (IL-1h4/IL-1f7) is processed by caspase-1 and mature IL-1f7b binds to the IL-18 receptor but does not induce IFN-γ production .Cytokine, 2002, 18(2): 61-71.
    [7] Sharma S, Kulk N, Nold MF, et al.The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines.J Immunol, 2008, 180(8): 5 477-482.
    [8] Jinnin M, Ihn H, Tamaki K.Characterization of SIS3,a novel specific inhibitor of Smad3,and its effect on transforming growth fator-betal-induced extracellular matrix expression .Mol Pharmacol, 2006, 69(2): 597-607.
    [9] Bulau AM, Fink M, Maucksch C, et al.In vivo expression of IL-37 reduces local and systemic inflammation in concanvalin A-induced hepatitis.Scientific World J, 2011, 11(11): 2 480-290.
    [10] Sakai N, Van Sweringen HL, Belizaire RM, et al.IL-37 reduces liver inflammatory injury via effects on hapatocytes and non-parenchymal cells .J Gastroenterol Hepatol, 2012, 27(10): 1 609-616.
    [11] Zhao JJ, Pan QZ, Pan K, et al.Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells .Sci Rep, 2014, 4(7503): 5 177.
    [12] Yan X, Zhao J, Zhang R.Interleukin-37 mediates the antitumor activity in colon cancer through β-catenin suppression.Oncotarget, 2017, 8(30): 49 064-075.
    [13] Akdis M, Burgler S, Crameri R, et al.Interleukins,1to37,and interferon-γ: Receptors, functions, and roles in disease .Allerg Clinical Immunol, 2011, 127(3): 701-721.
    [14] Kouchaki E, Tamtaji OR, Dadgostar E, et al.Correlation of serum levels of IL-33, IL-37, soluble form of vascular endothelial growth factor receptor 2 (VEGFR2), and circulatory frequency of VEGFR2-expressing cells with multiple sclerosis severity.Iran J Allergy Asthma Immunol, 2017, 16(4): 329-337.
    [15] Liu L, Feng K, Wang ML, et al.Expression of IL-37 in peripheral blood of adults with primary immune thrombocytopenia.Zhonghua Xueyexue Zazhi, 2017, 38(7): 628-631.
    [16] Yu K, Min X, Lin Y, et al.Increased IL-37 concentrations in patients with arterial calcification .Clin Chim Acta, 2016, 461: 19-24.
    [17] Chai M, Zhang HT, Zhou YJ.Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification.J Geriatr Cardiol, 2017, 14(5): 285-291.
    [18] 黄瑛, 林英忠, 施莹, 等, 急性冠状动脉综合症患者血浆IL-37变化水平及意义.实用医学杂志, 2014, 30(10): 1 559-561.
    [19] Liu K, Tang Q, Zhu X, et al.IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction .Clin Chim Acta, 2017, 468: 140-144.
    [20] Ji Q, Zeng Q, Huang Y, et al.Elevated Plasma IL-37, IL-18, and IL-18BP Concentrations in Patients with acute coronary syndrome .Mediators Inflamm, 2014, 2014: 165 742.
    [21] 周亚光, 吴惠惠, 彭春霞, 等, 急性ST段抬高型心肌梗死患者血清IL-37、TGF-β的表达及其意义.中国医药导报, 2017, 14(20): 58-61.
    [22] Conti P, Carinci F.Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells.Immunol Res, 2017, 65(5): 982-986.
    [23] Ji Q, Meng K, Yu K, et al.Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice .Sci Rep, 2017, 7(1): 3 310.
    [24] Luo Y, Cai X, Liu S.Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells .Proc Natl Acad Sci USA, 2014, 111(42): 15 178-183.
    [25] Huang J, Hou FL, Zhang AY, et al.Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis .Genet Mol Res, 2016, 15(2): 1-6
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

WU Hui-Hui, PENG Chun-Xia, WEI Qun, RU Zhao, DOU Ya-Jing, LIU Ya-Nan, ZHOU Ya-Guang. Research progress of the relationship between interleukin-37 and atherosclerosis[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2018,26(2):213-216.

Copy
Share
Article Metrics
  • Abstract:1131
  • PDF: 899
  • HTML: 0
  • Cited by: 0
History
  • Received:July 06,2017
  • Revised:September 29,2017
  • Online: March 07,2018
Article QR Code

You are the 48412 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025